⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PGEN News
Precigen, Inc. Common Stock
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
prnewswire.com
PGEN
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
prnewswire.com
PGEN
Form 8-K
sec.gov
PGEN
Precigen Reports First Quarter 2026 Financial Results and Business Updates
prnewswire.com
PGEN
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
accessnewswire.com
PGEN
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
prnewswire.com
PGEN
Form 8-K
sec.gov
PGEN
Precigen Reports Full Year 2025 Financial Results and Business Updates
prnewswire.com
PGEN
ProgenyHealth Releases 2026 Maternal & Infant Health Trends Report
prnewswire.com
PGEN
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
prnewswire.com
PGEN